Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Catching Investors' Attention Today

U.S. markets opened lower on Tuesday in a truncated week after rising bond yields dragged major stocks and growth indices. The yield on benchmark 10-year Treasuries rose more than 10 basis points to 3.858% as investors and traders began pricing in the possibility of a recession in 2023 and China eased further. its COVID-19 restrictions. Economic publications in the United States said the expected merchandise trade deficit for November fell to $83.35 billion from $98.8 billion in the previous month, while a separate report showed continued difficulties for the housing market as house prices fell below rising mortgage rates, Reuters reported. In the meantime, here are the five stocks that are catching investors' attention:

1. Tesla Inc TSLA: Shares of Tesla closed down 11.41% on Tuesday after a Reuters report said the company intended to run a reduced production schedule in January at its Shanghai factory, raising concerns about demand. The stock fell to its lowest level in more than two years.

Also read: Best Penny Stocks

2. Apple Inc AAPL: Shares of Apple closed down 1.39% on Tuesday. Japan has reportedly asked the iPhone maker to pay 13 billion yen ($98 million) in additional taxes for wholesale sales of iPhones and other Apple devices to overseas tourists, who were wrongly exempted from the consumption tax.

3. Lightjump Acquisition Corp LJAQ: Shares of Lightjump closed 100% higher on Tuesday. The company's shareholders have approved its combination with Moolec Science, according to Marketwatch.

4. Southwest Airlines Co LUV: Shares of Southwest closed down 5.94% on Tuesday after the airline canceled thousands of flights, drawing the attention of authorities. The U.S. Department of Transportation said late Monday it would investigate whether the company's disproportionate share of canceled flights was under its control, Yahoo Finance reported.

5. Gilead Sciences, Inc. GILD: Shares of the company closed up 0.31% on Tuesday. The company announced that it will acquire all remaining rights to the GS-1811 immunotherapy potential from Jounce Therapeutics.

Read more: COVID-19 cases soar as stocks soar: How to play China's reopening on the market

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.